Download

Download Full Text (1.4 MB)

Keywords

Immunology, Autoimmunity, CAAR T cells, B cells

Abstract

  • Graves’ Disease (GD) is the 4th most common autoimmune disease in the United States.
  • GD is characterized by autoreactive B cells releasing anti-thyroid stimulating hormone receptor (TSHR) Ab that bind to TSHR, causing an overexpression of hormones.
  • Excessive hormonal release leads to hyperthyroidism, causing a variety of metabolic issues.
  • No cure exists, only limited effectiveness of treatments, including chemotherapy, radiation, or thyroidectomy.
  • Chimeric antigen receptors (CAR) T cell therapy has been effective in treating blood cancers.
  • Modifying this therapy by engineering T cells that replace the antigen as the T cell receptor will selectively target autoreactive B cells, namely chimeric autoantibody receptor (CAAR) T cell therapy.
  • By using TSHR as the binding domain, we believe that our CAAR T cell that will be able to eliminate anti-TSHR B cells in GD.

Document Type

Article

Publication Date

2025

Language

English

College

Life Sciences

Department

Microbiology and Molecular Biology

University Standing at Time of Publication

Junior

Engineering Chimeric Autoantibody Receptor T cells (CAAR): a potential cure for Graves' Disease

Included in

Microbiology Commons

Share

COinS